Stock Earnings

Question 1

Monte Rosa Therapeutics Incの主要な財務諸表は何ですか？

Accepted Answer

最新の財務諸表（Form-10K）によると、Monte Rosa Therapeutics Incの総資産は$438で、純lossは$-72です。

Question 2

GLUEの主要な財務比率は何ですか？

Accepted Answer

Monte Rosa Therapeutics Incの流動比率は2.03、純利益率は-96、1株当たり売上高は$1.01です。

Question 3

Monte Rosa Therapeutics Incの収益はセグメントまたは地域別にどのように分けられていますか？

Accepted Answer

Monte Rosa Therapeutics Inc largest revenue segment is Novel Small Molecule Precision Medicines, at a revenue of 75,622,000 in the most earnings release.For geography, United States is the primary market for Monte Rosa Therapeutics Inc, at a revenue of 75,622,000.

Question 4

Monte Rosa Therapeutics Incは収益を上げていますか？

Accepted Answer

no、最新の財務諸表によると、Monte Rosa Therapeutics Incの純lossは$-72です。

Question 5

Monte Rosa Therapeutics Incに負債はありますか？

Accepted Answer

yes、Monte Rosa Therapeutics Incの負債は215です。

Question 6

Monte Rosa Therapeutics Incの発行済株式数は何株ですか？

Accepted Answer

Monte Rosa Therapeutics Incの総発行済株式数は61.5株です。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	177	75	0	0	0	0
Revenue Growth (YoY)	3,440%	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	33	43	39	35	15	4
Research & Development	129	112	103	77	57	24
Operating Expenses	163	156	143	112	72	28
Other Non Operating Income (Expenses)	--	--	--	0	0	-7
Pretax Income	28	-70	-135	-108	-73	-35
Income Tax Expense	4	2	0	--	--	--
Net Income	24	-72	-135	-108	-73	-35
Net Income Growth	-118%	-47%	25%	48%	109%	400%
Shares Outstanding (Diluted)	82.18	73.91	51.39	47.23	46.54	44.49
Shares Change (YoY)	15%	44%	9%	1%	5%	0%
EPS (Diluted)	0.28	-0.98	-2.63	-2.3	-1.59	-0.81
EPS Growth	-115.99%	-63%	15%	45%	96%	376%
Free Cash Flow	23	38	-62	-105	-69	-26
Free Cash Flow Per Share	0.27	0.51	-1.2	-2.22	-1.48	-0.58
Gross Margin	--	--	--	--	--	--
Operating Margin	7.9%	-108%	0%	0%	0%	0%
Profit Margin	13.55%	-96%	0%	0%	0%	0%
Free Cash Flow Margin	12.99%	50.66%	0%	0%	0%	0%
EBITDA	22	-73	-137	-109	-70	-28
EBITDA Margin	12.42%	-97.33%	0%	0%	0%	0%
D&A For EBITDA	8	8	6	3	2	0
EBIT	14	-81	-143	-112	-72	-28
EBIT Margin	7.9%	-108%	0%	0%	0%	0%
Effective Tax Rate	14.28%	-2.85%	0%	--	--	--

Monte Rosa Therapeutics Inc (GLUE) Price

GLUE Stock Price Chart

GLUE Income

Follow-Up Questions